PBM
AGIO icon

Propel Bio Management’s Agios Pharmaceuticals AGIO Stock Holding History

Propel Bio Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,792
Closed -$129K – 29
2023
Q4 		$129K Buy
+5,792
New +$130K 0.11% 33

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Propel Bio Management's AGIO Position: Q1 2024 in Review

Propel Bio Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2024, closing a stake of 5,792 shares — an estimated $129K sold.

Propel Bio Management first reported a position in AGIO in Q4 2023 and held it in 1 quarter. The position peaked at $129K in Q4 2023. 186 funds tracked by Wall St. Rank hold AGIO as of Q1 2024.

  • Propel Bio Management reported no remaining Agios Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Propel Bio Management sold 5,792 Agios Pharmaceuticals shares in Q1 2024, an estimated $129K.
  • Propel Bio Management first reported a position in Agios Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Propel Bio Management's Agios Pharmaceuticals position peaked at $129K in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2024.

Based on Propel Bio Management's 13F filing for Q1 2024, filed 13 May 2024.